FAMILYCARE.BO · BSE
FAMILY CARE HOSPITALS LIMITED
₹2
+0.50% (+₹0.01)
Prev. close
₹1.99
Volume
48,583
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About FAMILY CARE HOSPITALS LIMITED
Family Care Hospitals Limited engages in the healthcare services business in India. The company offers general surgeries, gynecology, orthopedics, ENT, cardiology, urology, oncology, plastic surgery, and proctology services. It is also involved in the operation of an online pharmacy application, as well as offers solutions for various therapeutics areas, including cardiology, dermatology, diabetology, gastroenterology, general-laparoscopy-surgery, hematology, internal-medicine, nephrology, neuro-surgery, neurology, nutrition-dietician, ophthalmology, orthopaedics, paediatrics-neonatology, physiotherapy, plastic-cosmetic-surgery, psychiatry-clinical-psychology, pulmonology, radiology, spine-surgery, and thoracic-cardiac-surgeon. The company was formerly known as Scandent Imaging Limited and changed its name to Family Care Hospitals Limited in September 2022. Family Care Hospitals Limited was incorporated in 1994 and is based in Thane, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Mr. Suchit Raghunath Modshing
Headquarters
Thane
Employees
8
Website
familycarehospitals.comExchange
View on BSE ↗Key stats
Market cap
₹10.80 Cr
EPS (TTM)
₹-1.30
Beta (1Y · daily vs NIFTY 50)
0.76
Beta (5Y · monthly vs NIFTY 50)
-0.61
Shares float
4.41 Cr
EPS · quarter ended Jun 2026
₹-0.08
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹42.04 Cr | ₹40.01 Cr | ₹7.90 Cr | ₹20.97 L | |
| EBITDA | — | ₹9.31 Cr | ₹9.94 Cr | ₹-43.05 Cr | ₹-7.43 Cr |
| — | ₹5.26 Cr | ₹12.55 Cr | ₹-44.15 Cr | ₹-8.68 Cr | |
| Diluted EPS | ₹1.27 | ₹1.56 | ₹2.32 | ₹-8.17 | ₹-1.61 |
Revenue, Depreciation & amortisation, EBITDA, Net income, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹74.58 Cr | ₹69.96 Cr | ₹46.09 Cr | ₹43.08 Cr | |
| ₹4.32 Cr | ₹3.66 Cr | ₹3.39 Cr | ₹5.17 Cr | |
| Stockholders' equity | ₹45.81 Cr | ₹58.37 Cr | ₹13.46 Cr | ₹9.45 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹-5.26 Cr | ₹-37.46 L | ₹-17.32 Cr | ₹-6.04 Cr | |
| Investing cash flow | — | ₹-1.54 Cr | ₹-41.03 L | ₹65.00 L | ₹0 |
| — | ₹25.87 Cr | ₹-1.04 Cr | ₹-55.28 L | ₹6.07 Cr | |
| Capital expenditure | ₹-33.51 L | ₹-2.05 Cr | ₹-44.53 L | ₹-26.96 L | — |
| End cash position | — | ₹19.28 Cr | ₹17.46 Cr | ₹23.58 L | ₹26.40 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| FAMILY CARE HOSPITALS LIMITED | ₹10.80 Cr | ₹1.99 | — | 1.14 | -91.8% | 0.55 | -97.3% | -56.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 20
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.